BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that the United States Patent and Trademark Office has issued the first patent for the company’s investigational product candidate Lenocta™ (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled “Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases,” encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.
